The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

By J. Canon, K. Rex, A. Y. Saiki, C. Mohr, K. Cooke, Dhanashri Bagal, Kevin Gaida, T. Holt, Charles G. Knutson, Neelima Koppada and 24 more. Nature, 2019

1,899 citations recorded by the source corpus.

Subfields: Immunology and Allergy, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/2e3f10aead17d509ca845eff2e3e082777552034

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Guo
2. Haolan Wang
3. Yongheng Chen
4. Hudie Wei

Citations in the corpus

• Harnessing multimodal data integration to advance precision oncology (2021, background): “However, recent evidence shows that small models without pretraining, such as ResNet-50, for small medical imaging datasets can perform comparably to pretrained large models 63 .”
• Targeting p53 pathways: mechanisms, structures and advances in therapy (2023, background): “As technology advances, many undruggable targets are becoming druggable, such as KRAS.”
• The frequency of Ras mutations in cancer (2020, neutral): “Compounds developed by Mirati, Wellspring, Janssen, and Amgen have now entered phase I/II clinical trials and Amgen recently reported the initial results of their trials with AMG 510 where it was tolerated by patients and stabilized or partially regressed their non– small cell lung tumors (55).”